Leap Therapeutics (NASDAQ:LPTX) Earns Neutral Rating from HC Wainwright

Leap Therapeutics (NASDAQ:LPTX)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a report released on Thursday,Benzinga reports.

Other equities analysts have also issued reports about the stock. Baird R W lowered shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th. Robert W. Baird downgraded Leap Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $9.00 to $1.25 in a report on Wednesday, January 29th.

Leap Therapeutics Price Performance

Leap Therapeutics stock opened at $0.32 on Thursday. The business has a 50 day simple moving average of $0.69 and a 200 day simple moving average of $2.17. The company has a market capitalization of $12.13 million, a PE ratio of -0.16 and a beta of 0.35. Leap Therapeutics has a one year low of $0.31 and a one year high of $4.79.

Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02. Equities analysts anticipate that Leap Therapeutics will post -1.84 earnings per share for the current fiscal year.

Institutional Trading of Leap Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prosperity Wealth Management Inc. bought a new position in shares of Leap Therapeutics in the 4th quarter valued at about $63,000. HighTower Advisors LLC acquired a new position in Leap Therapeutics in the third quarter valued at approximately $65,000. Jane Street Group LLC acquired a new position in Leap Therapeutics in the fourth quarter valued at approximately $107,000. Dauntless Investment Group LLC bought a new position in Leap Therapeutics in the fourth quarter valued at approximately $144,000. Finally, NewEdge Advisors LLC grew its holdings in Leap Therapeutics by 1,668,066.7% during the 4th quarter. NewEdge Advisors LLC now owns 50,045 shares of the company’s stock worth $144,000 after acquiring an additional 50,042 shares during the period. 30.46% of the stock is owned by institutional investors.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.